<DOC>
	<DOCNO>NCT00790933</DOCNO>
	<brief_summary>The purpose multicenter , open-label study collect data occurrence important clinical safety event result chronic vedolizumab ( MLN0002 ) administration .</brief_summary>
	<brief_title>An Open-label Study Vedolizumab ( MLN0002 ) Participants With Ulcerative Colitis Crohn 's Disease</brief_title>
	<detailed_description>The drug test study call vedolizumab . Vedolizumab test treat people ulcerative colitis Crohn 's disease . This study determine safety profile long-term vedolizumab treatment . The study enrol 2243 patient . Participants receive either placebo vedolizumab 300 mg IV infusion every 4 8 week previous vedolizumab study receive : â€¢ Vedolizumab 300 mg All participant receive vedolizumab intravenous infusion every 4 week 46 month . This multicenter trial conduct worldwide . The overall time participate study March 2016 vedolizumab available country participant reside , participant withdrawal , whichever come first . Participants make multiple visit clinic 16 week receive last dose vedolizumab follow 2-years safety questionnaire administer telephone follow-up assessment .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Vedolizumab</mesh_term>
	<criteria>1 . Previous treatment Study C13004 ( NCT00619489 ) , Study C13006 ( NCT00783718 ) , Study C13007 ( NCT00783692 ) , Study C13011 ( NCT01224171 ) , opinion investigator , well tolerate OR b . Moderate severe Crohn 's disease ulcerative colitis previously treat vedolizumab ( MLN0002 ) 2 . May receive therapeutic dose conventional therapy Crohn 's disease ulcerative colitis define protocol 1 . Development new , unstable , uncontrolled disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>